Opinion|Videos|October 25, 2024
Key Takeaways on Recent Advances in SCLC
Key Takeaways
- Tarlatamab represents a significant advancement in SCLC treatment, offering new hope beyond first-line therapies.
- Clinical trials are investigating novel immunotherapies and targeted treatments, showing promise for SCLC management.
Panelists discuss how the landscape of small cell lung cancer (SCLC) treatment is rapidly evolving, highlighting key advances in immunotherapy, targeted treatments like tarlatamab, and ongoing research efforts, while emphasizing the importance of early diagnosis, appropriate staging, and personalized treatment approaches to improve patient outcomes and quality of life.
Advertisement
Episodes in this series
We’ve discussed first-line therapies and a newly approved therapy tarlatamab.
- Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
- What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?
How do you see the management of SCLC evolving in the future?
Advertisement
Related to this article
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
Advertisement
Advertisement
Trending on AJMC
1
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
4
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
5